A Health Canada authorized digital therapeutic for IBS.
Regulora® is a prescription-free, drug-free digital therapeutic that delivers gut-directed hypnotherapy through a mobile app. Built on the North Carolina Protocol, and distributed by Launchit Solutions under Health Canada authorization.
A 12-week, app-delivered course of gut-directed hypnotherapy for people living with IBS.
IBS is one of the most prevalent functional GI conditions in Canada. The drug toolkit is limited, side effects are common, and gut-directed hypnotherapy has stronger guideline support than most patients ever hear about. The barrier has always been access.
Regulora® removes the access barrier. A clinically validated protocol, delivered in an app, at a fraction of the cost of in-person hypnotherapy, with no waitlist and no appointment scheduling.
- 7 self-administered sessions, 30 minutes each, one every other week
- 12 weeks to lasting results, because the brain-gut axis is what is being retrained
- Drug-free, no prescription required, works alongside any current IBS treatment
- One-time payment, no subscriptions
- Available on iOS and Android
Patient-reported outcomes from the North Carolina Protocol delivered through Regulora®.
87%
of participants would recommend Regulora® to others
68%
reported overall satisfaction with the treatment
12 weeks
to lasting symptom relief, without ongoing app use
Gut-directed hypnotherapy is not alternative medicine. It is in the Canadian Association of Gastroenterology Clinical Practice Guidelines for IBS, and Regulora® is the Health Canada authorized way to deliver it digitally
Authorized, guideline-supported, and clinically validated.
Regulora® is not a wellness app with a clinical claim. It is a regulated digital therapeutic with peer-reviewed evidence behind it.
Health Canada Authorized
Launchit Solutions Inc. is authorized by Health Canada to sell Regulora® in Canada as a digital therapeutic for IBS.
Clinical Practice Guidelines
Gut-directed hypnotherapy is included in the Canadian Association of Gastroenterology’s Clinical Practice Guidelines for the Management of IBS.
North Carolina Protocol
Developed by experts in gut-brain axis research with years of published clinical evidence behind it.
A non-pharmacological IBS option that fits into existing care plans.
Regulora® is a take-home option that supports patients between visits without adding a prescription, a side effect profile, or a referral wait. It works alongside existing IBS treatment, not in place of it.
- For clinicians. No prescription required. A non-drug option for patients who have exhausted or do not tolerate pharmacotherapy.
- For manufacturers. Co-promotion alongside a complementary IBS therapy or inclusion in a PSP as a non-drug adherence aid.
- For employers and insurers. One-time covered benefit for members managing IBS, with measurable patient-reported outcomes.
- For distributors. International market entry where digital therapeutic regulation supports it. Configuration, not new builds.
Ready to talk Regulora®?
Patients can buy Regulora® directly. Clinicians, manufacturers, employers, and distributors can scope a partnership in a single call.